Sentiment-Signal
25,6
Bearisch
Composite Score (0–100)
Insider (25%)
0
Keine Insider-Käufe
Institutionell (22,5%)
0
Keine neuen Positionen
Aktivist (12,5%)
0
Kein 13D/13G
Risikofreier Zins (T-Bills): 3,70% (Stand: 31.03.2026)
Score-Verlauf (90 Tage)
Kritische 8-K Meldungen
| Datum | Meldung | Schwere | Filing | Auszug |
|---|---|---|---|---|
| 01.07.2025 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; |
| 04.10.2024 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; |
| 05.09.2024 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | tive Officers The information set forth in Item 5.02 of this Current Report on Form 8-K under the heading “Appointment |
| 23.04.2024 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | 3(a) of the Exchange Act. ☐ Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment o |
| 04.04.2024 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | 3(a) of the Exchange Act. ☐ Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment o |
| 06.02.2024 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | ection 13(a) of the Exchange Act. ☐ Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appoi |
| 31.01.2024 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | ection 13(a) of the Exchange Act. ☐ Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appoi |
| 04.12.2023 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | ection 13(a) of the Exchange Act. ☐ Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appoi |
| 13.02.2023 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | 13(a) of the Exchange Act. ☐ Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointmen |
Stammdaten
Oruka Therapeutics, Inc. is a biotechnology company, which focuses on developing novel monoclonal antibody therapeutics for PsO and other I&I indications. Its pipeline includes ORKA-001 and ORKA-002. The company is headquartered in Menlo Park, CA.
Unternehmen & Branche
| Name | Oruka Therapeutics, Inc. |
|---|---|
| Ticker | ORKA |
| CIK | 0000907654 |
| Boerse | US |
| Sektor | Healthcare |
| Industrie | Biotechnology |
| SIC | 2834 · Pharmaceutical Preparations |
Wertpapier & Kennzahlen
| CUSIP | – |
|---|---|
| ISIN | – |
| Typ | Common Stock |
| Marktkapitalisierung | 2,52 Mrd. USD |
| Beta | -0,61 |
| Dividendenrendite | 19,36 % |
Externe Quellen: SEC EDGAR » · FMP-Profil » · Yahoo Finance »
Finanzkennzahlen (SEC XBRL)
| Periode | Filing | Umsatz | Nettoergebnis | EPS | Aktiva | Eigenkapital |
|---|---|---|---|---|---|---|
| 2025-12-31 | 10-K | -105,433,000 | 488,617,000 | 471,930,000 | ||
| 2025-09-30 | 10-Q | -30,277,000 | 509,251,000 | 486,791,000 | ||
| 2025-06-30 | 10-Q | -24,574,000 | -0.46 | 357,418,000 | 343,642,000 | |
| 2025-03-31 | 10-Q | -20,999,000 | -0.40 | 377,112,000 | 364,725,000 | |
| 2024-12-31 | 10-K | -83,724,000 | -3.87 | 396,019,000 | 382,221,000 | |
| 2024-09-30 | 10-Q | -28,623,000 | -1.46 | 414,090,000 | 342,368,000 | |
| 2024-06-30 | 10-Q | 0 | -22,243,000 | -6.96 | 33,844,000 | -28,981,000 |
| 2024-03-31 | 10-Q | 0 | -7,077,000 | -2.21 | 36,706,000 | -7,059,000 |
| 2023-12-31 | 10-K | 0 | -5,339,000 | -0.37 | 37,861,000 | 37,020,000 |
| 2023-12-31 | 10-Q | -1,089,000 | 37,861,000 | 37,020,000 | ||
| 2023-09-30 | 10-Q | 0 | -1,424,000 | -0.10 | 39,184,000 | 37,968,000 |
| 2023-06-30 | 10-Q | 0 | -1,480,000 | -0.10 | 41,083,000 | 39,238,000 |
| 2023-03-31 | 10-Q | 0 | -1,346,000 | -0.09 | 42,059,000 | 40,531,000 |
| 2022-12-31 | 10-Q | -1,174,000 | 43,085,000 | 41,673,000 | ||
| 2022-12-31 | 10-K | 0 | -9,926,000 | -0.69 | 43,085,000 | 41,673,000 |
| 2022-09-30 | 10-Q | 0 | -2,333,000 | -0.16 | 44,965,000 | 42,727,000 |
| 2022-06-30 | 10-Q | 0 | -3,147,000 | -0.22 | 48,101,000 | 44,963,000 |
| 2022-03-31 | 10-Q | 0 | -3,272,000 | -0.23 | 51,014,000 | 47,938,000 |
| 2021-12-31 | 10-Q | -5,676,000 | 54,924,000 | 51,043,000 | ||
| 2021-12-31 | 10-K | 0 | -19,322,000 | -1.39 | 54,924,000 | 51,043,000 |
Fondsaktivität (Vorquartalsvergleich)
Keine Fondsdaten für dieses Unternehmen vorhanden.
Insider-Transaktionen (12 Monate)
| Datum | Insider | Rolle | Typ | Stückzahl | Kurs | Wert (USD) | Δ | Trend |
|---|---|---|---|---|---|---|---|---|
| 2026-04-15 | Goncalves Joana | Officer, Chief Medical Officer | Open Market Sale | -2,273 | 66.56 | -151,300.65 | -171,3% | |
| 2026-04-15 | Goncalves Joana | Officer, Chief Medical Officer | Open Market Sale | -500 | 67.38 | -33,692.00 | -38,1% | |
| 2026-04-15 | Goncalves Joana | Officer, Chief Medical Officer | Open Market Sale | -4,227 | 65.73 | -277,836.91 | -314,5% | |
| 2026-03-16 | Klein Lawrence Otto | Director, Officer, Chief Executive Officer | Open Market Sale | -1,729 | 41.30 | -71,407.70 | -80,8% | |
| 2026-03-16 | Sandler Laura Lee | Officer, Chief Operating Officer | Open Market Sale | -600 | 41.30 | -24,780.00 | -28,0% | |
| 2026-03-16 | Goncalves Joana | Officer, Chief Medical Officer | Open Market Sale | -2,921 | 40.11 | -117,158.68 | -132,6% | |
| 2026-03-16 | Goncalves Joana | Officer, Chief Medical Officer | Open Market Sale | -2,902 | 41.20 | -119,568.78 | -135,3% | |
| 2026-03-16 | Goncalves Joana | Officer, Chief Medical Officer | Open Market Sale | -1,177 | 41.94 | -49,358.79 | -55,9% | |
| 2026-03-16 | Goncalves Joana | Officer, Chief Medical Officer | Open Market Sale | -641 | 41.30 | -26,473.30 | -30,0% | |
| 2026-03-16 | Quinlan Paul T | Officer, General Counsel | Open Market Sale | -733 | 41.30 | -30,272.90 | -34,3% | |
| 2026-03-16 | Agarwal Arjun | Officer, Senior Vice President, Finance | Open Market Sale | -395 | 41.30 | -16,313.50 | -18,5% | |
| 2026-03-02 | Sandler Laura Lee | Officer, Chief Operating Officer | Open Market Sale | -2,675 | 33.81 | -90,435.60 | -102,4% | |
| 2026-03-02 | Sandler Laura Lee | Officer, Chief Operating Officer | Open Market Sale | -2,325 | 33.28 | -77,386.00 | -87,6% | |
| 2026-02-17 | Goncalves Joana | Officer, Chief Medical Officer | Open Market Sale | -936 | 32.78 | -30,686.01 | -34,7% | |
| 2026-02-17 | Goncalves Joana | Officer, Chief Medical Officer | Open Market Sale | -6,064 | 32.30 | -195,872.66 | -221,7% | |
| 2026-01-15 | Goncalves Joana | Officer, Chief Medical Officer | Open Market Sale | -4,381 | 31.56 | -138,275.75 | -156,5% | |
| 2026-01-15 | Goncalves Joana | Officer, Chief Medical Officer | Open Market Sale | -2,619 | 32.24 | -84,428.70 | -95,6% | |
| 2026-01-02 | Sandler Laura Lee | Officer, Chief Operating Officer | Open Market Sale | -3,144 | 29.08 | -91,431.92 | -103,5% | |
| 2026-01-02 | Sandler Laura Lee | Officer, Chief Operating Officer | Open Market Sale | -8,748 | 28.17 | -246,396.17 | -278,9% | |
| 2026-01-02 | Sandler Laura Lee | Officer, Chief Operating Officer | Open Market Sale | -1,108 | 29.75 | -32,966.99 | -37,3% | |
| 2025-12-19 | Goncalves Joana | Officer, Chief Medical Officer | Open Market Sale | -1,492 | 30.70 | -45,806.04 | -51,8% | |
| 2025-12-19 | Goncalves Joana | Officer, Chief Medical Officer | Open Market Sale | -3,080 | 31.58 | -97,263.32 | -110,1% | |
| 2025-12-19 | Goncalves Joana | Officer, Chief Medical Officer | Open Market Sale | -1,787 | 29.62 | -52,934.51 | -59,9% | |
| 2025-12-19 | Goncalves Joana | Officer, Chief Medical Officer | Open Market Sale | -641 | 28.53 | -18,289.14 | -20,7% |
Top-Fondshalter
Keine Fondsdaten zu dieser Aktie vorhanden.